I agree but potential upside could be more. Valuation is low and with more upcoming catalyst events, could move higher as we get further down p3 and into FDA submission.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.